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The use of point-of-care meters for bedside blood glucose monitoring has become common in hospitalized patients. The management of patients in critical care units, those receiving aggressive supportive therapy, and those with type 1 or 2 diabetes may require frequent testing of their blood glucose concentrations [1] [2] [3] . Bedside monitoring is often done with capillary whole blood from a fingerstick, and these whole-blood glucose meters produce values 8 -10% lower than those in plasma [4] . However, most clinical laboratory instruments measure glucose concentrations in plasma or serum, not whole blood. A wholeblood glucose meter that reports a plasma-equivalent result might be useful to reduce possible confusion when comparing glucose meter and laboratory glucose values.
Here, we evaluated the SureStep ® -Pro Hospital System, a reflectance meter that uses glucose oxidase chemistry to report plasma-equivalent glucose concentrations from capillary, venous, and arterial whole blood. We compared whole-blood and plasma glucose concentrations measured by the SureStep-Pro Hospital System (LifeScan) with values from the One Touch ® II Hospital System (LifeScan), the Yellow Springs Instrument Model 2700 Select Biochemistry Analyzer (YSI), and the Vitros 750 Analyzer (Johnson & Johnson). Plasma equivalent results on the SureStep-Pro Hospital System are achieved by calibrating the meter to plasma glucose concentrations obtained from donor blood samples supplemented with glucose and measured on the YSI analyzer.
Capillary, venous, and arterial whole-blood samples were obtained from patients at Barnes-Jewish Hospital for whom routine glucose values by the central laboratory or glucose meter had been requested. This study had the approval of the Washington University School of Medicine Human Studies Committee. Patients for the study were selected such that glucose values covered a wide range of values. Whole-blood samples were analyzed with the SureStep-Pro Hospital System, the One Touch II Hospital System, and the YSI. Plasma glucose concentra-tions were obtained with the YSI and the Vitros 750. The effect of hematocrit (Hct) and Po 2 was examined by using the Stat-Crit (Wampole Labs.) instrument and the Radiometer ABL 505 blood gas analyzer (Radiometer Corp.), respectively. Low, normal, and high quality-control samples provided by LifeScan were used for precision studies on the SureStep-Pro Hospital System.
Day-to-day precision (CV) was 4.4% at a glucose concentration of 430 Ϯ 19 mg/L (n ϭ 20), 4.1% at a glucose concentration of 1008 Ϯ 41 mg/L (n ϭ 20), and 43% at a glucose concentration of 3175 Ϯ 136 mg/L (n ϭ 20) for the low, normal, and high controls, respectively.
Over the range of glucose concentrations tested (730 -4530 mg/L) in capillary blood, the SureStep-Pro Hospital System (mean SureStep ϭ 1710 mg/L) correlated well with whole-blood values measured by the One Touch II Hospital System and by the YSI (SureStep ϭ 1.13YSI ϩ 0.66, n ϭ 52, r 2 ϭ 0.987, S y͉x ϭ 90 mg/L; mean blood YSI ϭ 1500 mg/L). The SureStep-Pro Hospital System values averaged 10% and 14% higher, respectively, than the values from the One-Touch and YSI whole-blood analyzers. In contrast, the SureStep-Pro Hospital System both correlated with and closely matched values determined in plasma by the YSI (SureStep ϭ 1.04YSI Ϫ 0.17, n ϭ 52, r 2 In the capillary, venous, and arterial whole-blood samples with Hct determinations, we found no correlation between Hct and the difference between the SureStep-Pro Hospital System and YSI values. Fig. 1A shows the comparison of Hct and the difference between the Sure-Step-Pro Hospital System and Vitros values from venous samples. Similar findings were observed for capillary and arterial whole blood. Likewise, there was no correlation between the Po 2 and the difference between the SureStep-Pro Hospital System and YSI values in arterial whole blood (Fig. 1B) .
The SureStep-Pro Hospital System has excellent day-today precision and is capable of measuring glucose concentrations in capillary, venous, and arterial whole blood. The SureStep-Pro Hospital System provides glucose values essentially equivalent to those obtained from plasma, with Hct and Po 2 having no effect on the results. Taken together, these studies demonstrate that the SureStep-Pro Hospital System provides highly accurate plasma-equivalent results on whole-blood samples. This approach should help eliminate possible confusion when comparing bedside meter results with those from the clinical laboratory. Advances in planar (bio)sensors have allowed whole-blood diagnostics to be applied in testing close to the patient, resulting in rapid turnaround times, which are especially desirable in critical care settings. Several new technologies and custom chemicals had to be integrated to allow high performance, small sample size, fast response time, and cost-effective devices. (Bio)sensors described below are used for measurement of blood gases, blood electrolytes, glucose, and lactate in point-of-care environments.
Planar (Bio)Sensors for Critical Care Diagnostics, Paul
Manufacturing of planar thick-film electrodes on ceramic wafers is now done with standard processes yielding precise patterns through the use of ultrapure metals for prolonged use-life under constant polarization. A platinized carbon paste ink has been developed to screenprint the active electrode of the glucose and lactate biosensor (Fig. 1, top) .
In the amperometric sensor for Po 2 , Nafion (polymeric perfluorinated ionomer; Aldrich) is used as an internal electrolyte and is spin-coated with a custom-made, patented polymer [1] . This polymer has a relatively low permeability for oxygen but is permeable to water vapor to allow fast wetting and a stable steady-state response signal (Fig. 1, middle) .
For ion-selective sensors, a copolymer of methacrylamidopropyltrimethylammonium chloride and methyl methacrylate (MAPTAC/MMA) is used as a solid internal contact, resulting in minimal shifts in offset potential over Ͼ30 days [2] (Fig. 1, bottom) For enzyme sensors, we applied a combination of an interference rejection cover membrane (FC 61 from Dow Corning) [3] and a correcting electrode to cope with known interferences [4] . The glucose and lactate sensor are virtually free of interference at maximum expected values of the individual substances being tested (see [5, 6] for examples). FC 61, a silicone material spun-cast from an aqueous emulsion, rejects interferences and has a restricted permeability for the substrates (glucose and lactate) but a high permeability for oxygen, making the sensor oxygen-independent over the Po 2 range of 25-700 mmHg.
For biosensors we also were required to apply enzymestabilizing agents, such as polyvinylalcohol, to achieve extended lifetime in a multianalyte, multiuse application. The sensors are polarized at ϳϩ400 mV (vs Ag/AgCl). The use of platinum-activated carbon as the working electrode material permits these lower potentials to be used for the oxidation of hydrogen peroxide. The advantages of the lower operating potentials include a reduced interference from oxidizable substances in blood, which may permeate the FC 61 membrane, as well as the added benefit of extending sensor use-life ( Fig. 1 ).
